Pleasing Signs As A Number Of Insiders Buy Gossamer Bio Stock
Gossamer Bio Is Maintained at Buy by Goldman Sachs
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Is Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5?
Gossamer Bio Management to Meet With Oppenheimer
GOSSAMER BIO Earnings Preview: Recent $GOSS Insider Trading, Hedge Fund Activity, and More
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $10
Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Buy Rating for Gossamer Bio: Seralutinib's Transformative Potential in Pulmonary Hypertension
After Losing 0.7% in the Past Year, Gossamer Bio, Inc. (NASDAQ:GOSS) Institutional Owners Must Be Relieved by the Recent Gain
Gossamer Bio Reports 2024 Financial Results and Progress
Express News | Wedbush Reiterates Outperform on Gossamer Bio, Maintains $4 Price Target
Piper Sandler Sticks to Their Buy Rating for Gossamer Bio (GOSS)
Express News | Gossamer Bio: Seralutinib Receives Orphan Drug Designation for Pah in Japan
Gossamer Bio: Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Ops Into 1H of 2027 >GOSS
Gossamer Bio: PROSERA Phase 3 in PAH on Track for Topline Data Readout in 4Q
Gossamer Bio: Registrational Phase 3 in PH-ILD Expected to Commence in 2H >GOSS
Gossamer Bio Reports Q4 EPS (15c), Consensus (17c)
Gossamer Bio | 8-K: Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update